Institution Directory

Clinical trials at Northwestern Medicine

Sites in Chicago, IL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1129

Shown on this page

Current sort

Live official records

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Olomorasib, Pembrolizumab, Durvalumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 91
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 70 more

Conditions: Post Operative Atrial Fibrillation, Atrial Fibrillation, Postoperative
Interventions: Isolator® Synergy™ EnCompass® Ablation System and AtriClip® LAA Exclusion System; Device
Lead sponsor: AtriCure, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 960 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 33
States / cities: Scottsdale, Arizona • Jonesboro, Arkansas • San Diego, California + 27 more

Conditions: Ventral Hernia, Ventral Hernia Repair, Postoperative Pain
Interventions: Bupivicaine, Fentanyl, Thoracic epidural analgesia, Hydromorphone, Acetaminophen, Ketorolac, magnesium sulfate, Tramadol, Gabapentin, Cyclobenzaprine, transversus abdominis plane block; Drug · Device · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Peposertib, Placebo Administration; Procedure · Radiation · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 44
States / cities: Duarte, California • Irvine, California • Orange, California + 35 more

Conditions: Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Pembrolizumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 533
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 340 more

Conditions: Premature
Interventions: Enfamil® DHA & ARA Supplement for Special Dietary Use; Dietary Supplement
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: Up to 36 Weeks
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 7
States / cities: Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 2 more

Conditions: Systemic Lupus Erythematosus, Lupus Nephritis
Interventions: CABA-201; Biological
Lead sponsor: Cabaletta Bio; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 21
States / cities: Orange, California • Sacramento, California • New Haven, Connecticut + 14 more

Conditions: Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Neuroendocrine Tumor, Midgut Neuroendocrine Tumor G1, Neuroendocrine Tumor G2, Recurrent Digestive System Neuroendocrine Tumor G1, Regional Digestive System Neuroendocrine Tumor G1
Interventions: Biospecimen Collection, Computed Tomography, Echocardiography Test, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pazopanib Hydrochloride, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging; Procedure · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 412
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Anaheim, California + 263 more

Conditions: Multiple Myeloma
Interventions: Arlocabtagene Autoleucel; Biological
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 41
States / cities: Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 33 more

Conditions: Primary Biliary Cholangitis
Interventions: Seladelpar, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 54
States / cities: Birmingham, Alabama • Phoenix, Arizona • Lancaster, California + 40 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Pridopidine, Placebo; Drug
Lead sponsor: Prilenia; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 18
States / cities: Phoenix, Arizona • San Francisco, California • Aurora, Colorado + 14 more

Conditions: cGVHD
Interventions: Non-Interventional; Other
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 30 more

About this Northwestern Medicine institution page

What this page lists: ClinicalTrials.gov records that list Northwestern Medicine in Chicago, IL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Northwestern Medicine

Filter and sort this campus

Live official records

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

BoxX-NoAF Clinical Trial

Epidural Analgesia Versus Opioid-sparing Analgesia for Open Ventral Hernia Repair With Transversus Abdominis Release

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

About this Northwestern Medicine institution page